Zhan L, Su F, Li Q, Wen Y, Wei F, He Z
Front Pharmacol. 2023; 14:1257450.
PMID: 37693915
PMC: 10484417.
DOI: 10.3389/fphar.2023.1257450.
Peng Q, Hao L, Guo Y, Zhang Z, Ji J, Xue Y
World J Clin Cases. 2022; 10(13):3989-4019.
PMID: 35665115
PMC: 9131213.
DOI: 10.12998/wjcc.v10.i13.3989.
Kou L, Jiang X, Tang Y, Xia X, Li Y, Cai A
Bioact Mater. 2021; 9:15-28.
PMID: 34820552
PMC: 8586589.
DOI: 10.1016/j.bioactmat.2021.07.009.
Cheng N, Hsieh C, Fang Y, Liao C, Ng S, Wang H
EJNMMI Res. 2020; 10(1):74.
PMID: 32632638
PMC: 7338312.
DOI: 10.1186/s13550-020-00631-3.
Kim B, Chang J
Sci Rep. 2019; 9(1):13301.
PMID: 31527827
PMC: 6746783.
DOI: 10.1038/s41598-019-49928-x.
Roles of GLUT-1 and HK-II expression in the biological behavior of head and neck cancer.
Yang H, Zhong J, Zhou S, Han H
Oncotarget. 2019; 10(32):3066-3083.
PMID: 31105886
PMC: 6508962.
DOI: 10.18632/oncotarget.24684.
Prognostic role of glycolysis for cancer outcome: evidence from 86 studies.
Yu M, Chen S, Hong W, Gu Y, Huang B, Lin Y
J Cancer Res Clin Oncol. 2019; 145(4):967-999.
PMID: 30825027
DOI: 10.1007/s00432-019-02847-w.
Glucose transporter-1 as an independent prognostic marker for cancer: a meta-analysis.
Zhao Z, Lu L, Qiu J, Li Q, Xu F, Liu B
Oncotarget. 2018; 9(2):2728-2738.
PMID: 29416806
PMC: 5788674.
DOI: 10.18632/oncotarget.18964.
The prognostic value of GLUT1 in cancers: a systematic review and meta-analysis.
Yu M, Yongzhi H, Chen S, Luo X, Lin Y, Zhou Y
Oncotarget. 2017; 8(26):43356-43367.
PMID: 28498810
PMC: 5522151.
DOI: 10.18632/oncotarget.17445.
Immunoexpression of GLUT-1 and angiogenic index in pleomorphic adenomas, adenoid cystic carcinomas, and mucoepidermoid carcinomas of the salivary glands.
de Souza L, de Oliveira L, Nonaka C, Lopes M, Pereira Pinto L, Guedes Queiroz L
Eur Arch Otorhinolaryngol. 2017; 274(6):2549-2556.
PMID: 28299426
DOI: 10.1007/s00405-017-4530-y.
Glucose transporter GLUT1 expression and clinical outcome in solid tumors: a systematic review and meta-analysis.
Wang J, Ye C, Chen C, Xiong H, Xie B, Zhou J
Oncotarget. 2017; 8(10):16875-16886.
PMID: 28187435
PMC: 5370007.
DOI: 10.18632/oncotarget.15171.
Predictive value of glucose transporter-1 and glucose transporter-3 for survival of cancer patients: A meta-analysis.
Chen X, Lu P, Zhou S, Zhang L, Zhao J, Tang J
Oncotarget. 2017; 8(8):13206-13213.
PMID: 28086215
PMC: 5355089.
DOI: 10.18632/oncotarget.14570.
Prognostic value of GLUT-1 expression in oral squamous cell carcinoma: A prisma-compliant meta-analysis.
Li C, Sun J, Gong Z, Lin Z, Liu H
Medicine (Baltimore). 2016; 95(45):e5324.
PMID: 27828852
PMC: 5106058.
DOI: 10.1097/MD.0000000000005324.
Effects of topoisomerase inhibitors that induce DNA damage response on glucose metabolism and PI3K/Akt/mTOR signaling in multiple myeloma cells.
Demel H, Feuerecker B, Piontek G, Seidl C, Blechert B, Pickhard A
Am J Cancer Res. 2015; 5(5):1649-64.
PMID: 26175935
PMC: 4497433.
Glut-1 as a prognostic biomarker in oral squamous cell carcinoma.
Harshani J, Yeluri S, Guttikonda V
J Oral Maxillofac Pathol. 2015; 18(3):372-8.
PMID: 25948991
PMC: 4409181.
DOI: 10.4103/0973-029X.151318.
The Warburg effect: evolving interpretations of an established concept.
Chen X, Qian Y, Wu S
Free Radic Biol Med. 2014; 79:253-63.
PMID: 25277420
PMC: 4356994.
DOI: 10.1016/j.freeradbiomed.2014.08.027.
GLUT1 expression patterns in different Hodgkin lymphoma subtypes and progressively transformed germinal centers.
Hartmann S, Agostinelli C, Diener J, Doring C, Fanti S, Zinzani P
BMC Cancer. 2012; 12:586.
PMID: 23228169
PMC: 3537691.
DOI: 10.1186/1471-2407-12-586.
Immunohistochemical analysis of salivary gland tumors: application for surgical pathology practice.
Nagao T, Sato E, Inoue R, Oshiro H, Takahashi R, Nagai T
Acta Histochem Cytochem. 2012; 45(5):269-82.
PMID: 23209336
PMC: 3496863.
DOI: 10.1267/ahc.12019.
Expression of Glut-1, HIF-1α, PI3K and p-Akt in a case of ceruminous adenoma.
Shen W, Cheng K, Bao Y, Zhou S, Yao H
Head Neck Oncol. 2012; 4:18.
PMID: 22551172
PMC: 3414790.
DOI: 10.1186/1758-3284-4-18.
Carcinoma ex pleomorphic adenoma of the salivary glands: distinct clinicopathologic features and immunoprofiles between subgroups according to cellular differentiation.
Kim J, Kwon G, Roh J, Choi S, Nam S, Kim S
J Korean Med Sci. 2011; 26(10):1277-85.
PMID: 22022178
PMC: 3192337.
DOI: 10.3346/jkms.2011.26.10.1277.